Recent advances have introduced non-invasive immunodiagnostic strategies for urothelial carcinoma, notably assays for nuclear matrix protein−22 (NMP−22), bladder tumor antigen (BTA), and urinary cytology–based markers (uCyt+) (54–56). This evidence concerns the gene NUMA1 and urothelial carcinoma.